Variant Summary
- HGVS
- —
- Variant Type(s)
- transcript_amplification
- Evidence Items
- 11
Evidence Level Distribution
Level B: 10Level D: 1
Evidence Items
Showing CIViC evidence rows where gene = EGFR and variant = Amplification.
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| B | Prognostic | Supports | Poor Outcome | Head And Neck Squamous Cell Carcinoma | 4 | |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Gefitinib,Erlotinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Erlotinib,Gefitinib | 4 |
| B | Predictive | Does Not Support | Sensitivity/Response | Head And Neck Squamous Cell Carcinoma | Cetuximab,Platinum Compound,Fluorouracil | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | 4 |
| D | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Rociletinib,Osimertinib | 3 |
| B | Prognostic | Supports | Poor Outcome | Barrett's Adenocarcinoma | 3 | |
| B | Prognostic | Supports | Poor Outcome | Cervical Squamous Cell Carcinoma | 3 | |
| B | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Panitumumab,Cetuximab | 3 |
| B | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Cetuximab | 3 |
| B | Predictive | Does Not Support | Sensitivity/Response | Lung Non-small Cell Carcinoma | Gefitinib,Erlotinib | 2 |